Skip to main navigation menu Skip to main content Skip to site footer

No. 1 (2017)

NEW MEDICINES

Paliperidone Palmitate 3-Month Formulation (Trevicta) – a new word for the longterm therapy of patients with schizophrenia

Published 2017-03-30

  • E.V. Oleneva
    • ,
  • P.V. Ryvkin
    • ,
  • M.Ya. Ladyzhensky

E.V. Oleneva
Moscow Research Institute of Psychiatry - Branch of the V.P. Serbsky National Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation

P.V. Ryvkin
Federal Medical Research Centre for Psychiatry and Narcology by the name of V.P. Serbsky Minzdrava RF

M.Ya. Ladyzhensky
Federal Medical Research Centre for Psychiatry and Narcology by the name of V.P. Serbsky Minzdrava RF

Abstract

The article presents the most important results of clinical trials of a new paliperidone palmitate 3Pmonth formulation in intramuscular injections (Trevicta), and formulates the basic practical
recommendations for its application, designed to optimize its use for the treatment of patients with schizophrenia in terms of initiation of therapy and longPterm maintenance treatment.

Keywords

schizophrenia, compliance, longPterm maintenance treatment, long-acting antipsychotics, paliperidone palmitate 3-month formulation

PDF (Русский)

Downloads

Download data is not yet available.